5th Meeting on Acute Cardiac Care and Emergency Medicine, 2016 Vilnius

Slides:

Advertisements

Similar presentations

CoreValve – ICE Awards Italian CoreValve Experts Balloon valvuloplasty after Transcatheter Aortic Valve Implantation (TAVI): always safe? Dr Salvi A, Dr.

Advertisements

Ghanem et al., J Am Coll Cardiol 2010;55:1427–32..

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve ® has been approved. The CoreValve ® System is not currently approved in the USA,

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

Trileaflet Aortic Valve. Management strategy for patients with chronic severe aortic regurgitation. Preoperative coronary angiography should be performed.

When Does Baseline Left Ventricular Function Influence Survival Post Transcatheter Aortic Valve Implantation? —The CoreValve Australia New Zealand Study.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc

HEAPHY 1 & 2 CASE RACE 1 – DIAG Rowena OLIVER Sat 31 st Aug 2013 Session 3 / CR1-6 13:26 – 13:30 OTAGO / SOUTHLAND ABSTRACT A case of a 81 year old female.

University Heart Center Hamburg

TAVR Pearls Addressing the Shortcomings of the Current TAVR Generation

Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.

Pediatric Interventions Cardiac Catheterization and Valvuloplasty.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.

Osaka University Department of Cardiovascular Surgery Osaka University Department of Cardiovascular Surgery The efficacy of debranching TEVAR for arch.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.

Axel Linke University of Leipzig Heart Center, Leipzig, Germany Sabine Bleiziffer German Heart Center, Munich, Germany Johan Bosmans University Hospital.

Trancatheter Aortic Valve Implantation (TAVI)

Tri-leaflet Aortic Valve. Aortic Stenosis Nishimura, RA et al AHA/ACC Valvular Heart Disease Guideline.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc

Prosthetic heart valves: management of usual and unusual complications January 14 th, h-15h30.

Transcatheter Cardiovascular Therapeutics 2008 (October 12-17, 2008 · Washington, DC) First-in-Human Report: Initial Experience with a Stentless and Retrievable.

EXPANDING INDICATIONS OF TRANSCATHETER HEART VALVE INTERVENTIONS. JACC CARDIOVASCULAR INTERVENTION. DR.RAJAT GANDHI.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Aortic Valve Replacement Will Become.

Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,

TAVR in Patients With Chronic Kidney Disease

Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.

Trans- catheter aortic valve replacement vs

Late breaking news in heart valve disease

Pulmonary hypertension in patients with mitral valvular heart disease before and after surgical correction .

TAVR Medtronic CoreValve® Subclavian Approach Clinical Data

Nat. Rev. Cardiol. doi: /nrcardio

Anita W. Asgar MD, FRCPC, FACC Montreal Heart Institute

Trans-Catheter Aortic Pseudo-Aneurysm Repair

Patient Selection for TAVI:

Updates From NOTION: The First All-Comer TAVR Trial

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.

Trans-Apical Aortic Valve Implant:

TAVR in Patients with Chronic Lung Disease

Vilnius University Hospital Santariskiu Clinics

The Spanish Data Bank PEGASO M. Martínez-Sellés

Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.

Pediatric cardiac catheterization Part 1 - balloon procedures David Shim, MD The Heart Center Children’s Hospital Medical Center Cincinnati, Ohio.

Giuseppe Tarantini MD, PhD

Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,

Management strategy for patients with aortic stenosis

TAVI „Catch me if you can!“

Early Feasibility Studies Investigator Perspective

Longevity of transcatheter and surgical bioprosthetic aortic valves in patients with severe aortic stenosis and lower surgical risk Lars Sondergaard,

Niv Ad, MD Chief, Cardiac Surgery Professor of Surgery, VCU

CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,

Axel Linke University of Leipzig Heart Center, Leipzig, Germany

Annual Outcomes With Transcatheter Valve Therapy

One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.

University Heart Center Hamburg

Balloon-Expandable Transcatheter Valve System : OUS Data

Is Open Heart Surgery Too Risky For You? Opt for a Minimally Invasive Procedure.

Annual Outcomes With Transcatheter Valve Therapy

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 3D printing of aortic and mitral valves

Median total new lesion volume

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 TAVI for bicuspid aortic valve disease

Figure 2 A patient with aortic stenosis and mitral regurgitation

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Suggested pathway for assessment of aortic valve replacement dysfunction. Suggested pathway for assessment of aortic valve replacement dysfunction. Transthoracic.

Aortic and innominate routes for transcatheter aortic valve implantation Jean Porterie, MD, Nicolas Mayeur, MD, PhD, Thibaut Lhermusier, MD, PhD, Nicolas.

Presentation transcript:

5th Meeting on Acute Cardiac Care and Emergency Medicine, 2016 Vilnius Transcatheter aortic valve implantation (TAVI) complicated by acute bronchial bleeding I. Norkienė1, R. Samalavičius1, K. Ručinskas2, P. Šerpytis 2 1.Vilnius University, Faculty of medicine, Vilnius, Lithuania 2. Clinic of Cardiovascular Diseases, Vilnius University Hospital Santariškiu Klinikos. Vilnius, Lithuania 5th Meeting on Acute Cardiac Care and Emergency Medicine, 2016 Vilnius Introduction: Transcatheter aortic valve implantation (TAVI) has been increasingly used as a preferred treatment for severe symptomatic aortic stenosis in inoperable and high surgical risk patients. The role of TAVI is expanding – newer indications for its use are under research. There is growing interest for the application of TAVI in lower surgical risk patients or in patients with anatomical difficulties. Post – procedural course: 2 hours after procedure - massive hemoptysis. Endobronchial obturation of left main bronchus. No contrast extravasation or signs of pulmonary embolization in angio CT. Foam obturator to occlude upper left bronchus for 2 days. Obturator removed, with no more signs of obvious bleeding and no indication to other treatments. Patient was discharged from hospital NYHA II Case report: A 73-year-old woman Symptomatic aortic valve stenosis. 0,7 cm2 Aortic coarctation interposition graft 50 years ago (1964). Valvuloplasty successfully done 1 year ago. NYHA functional class was III. EuroSCORE II was 2,64 % STS predicted mortality was 2.3 %. The patient rejected conventional surgery. After multidisciplinary evaluation TAVI as an alternative strategy was suggested and risks explained to the patient. The patient consented and accepted the risks of intervention. TAVI: 26 mm Core Valve nitinolporcine prosthesis. Right femoral artery and an 18 Fr (6 mm) Malpositioning of the valve and attempts to correct it ended up with valve stuck in aorta below subclavian artery. After procedure valve left in descending aorta. Figure 3. Obturation of lef main bronchus and complete collapse of the left lung Figure 4. Three-dimensional reconstruction for the CT angiography showing CoreValve position in the aortic arch Figure 1. Two-dimensional echocardiographic evaluation Gradient through aortic valve 27.5 mmHg Aortic valve area 0.7 cm2 Aortic insufficiency I degree. Figure 4 . Chest xray before the discharge Figure 2. Cardiac catheterization angiography showing the misplacement of TAVI Conclusion: Multidisciplinary heart valve team should determine the choice of the treatment for aortic valve stenosis in high surgical risk patient. Operators should pay thorough attention and be prepared for challenging anatomic characteristics of the individual patient. Refferences: DR Holmes, MJ Mack, S Kaul, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012; 59:1200. O’Sullivan, P Wenaweser. Optimizing clinical outcomes of transcatheter aortic valve implantation patients with comorbidities Expert Rev Cardiovasc Ther. 2015 Dec;13(12):1419-32.